People diagnosed with wet macular degeneration in the Cape Breton, Nova Scotia area will now have access to lucentis as a treatment option. Premier Darrell Dexter made the announcement indicating that that both Lucentis and Avastin treatments will be made available for people who have Pharmacare in the province.
Wet Macular Degeneration is the most severe form of the eye disease that attacks the central vision of those people infected. Abnormal blood vessels leak, causing blood to build up behind the retina, limiting the central vision of people with the eye disease.
Lucentis and its off-label cousin Avastin have been the primary weapons used in treating this form of macular degeneration. Lucentis is the preferred method of treatment used because it is approved for use in the eye. Avastin is the off-label drug used primarily to treat cancer but has shown great results in treating wet macular degeneration as well.
This announcement gives those suffering from this degenerative eye disease access to treatment closer to their homes.
Age-related macular degeneration is the leading cause of vision loss in Canada and is estimated to affect nearly 4,000 people in Nova Scotia alone.